Table 2.
Characteristics of the patients at baseline (n = 31) and study characteristics.
| Characteristics | |
|---|---|
| n (%) | |
| Sex: women | 17 (55) |
| Responsibility for pharmacotherapy | |
| Patient only | 2 (6) |
| Patient supported by caregiver | 6 (19) |
| Caregiver only | 22 (71) |
| Professional care only | 1 (3) |
| Antidementia drugs in MEMSa | |
| Donepezil | 12 (39) |
| Galantamine | 12 (39) |
| Memantine | 7 (23) |
| Rivastigmine | 1 (3) |
| Regimen of antidementia drug in MEMSa | |
| Once daily | 24 (75) |
| Twice daily | 8 (25) |
| median (range) | |
| Age in years | 76 (47-96) |
| Duration of MEMS monitoring in daysb | 180 (140-180) |
| Duration of antidementia pharmacotherapy at inclusion in months | 18 (0-78) |
| Number of regularly administered drugs | 6 (2-12) |
MEMS, medication event monitoring system; a one patient was started on donepezil (MEMS monitoring during 49 days), but later in the course of the study he was switched to memantine (MEMS monitoring during 111 days); b eight out of 31 patients (26%) had non-monitored periods (e.g. due to hospital stays) or incomplete follow-up of less than 180 days.